Nerve technology developer Orthocell (ASX:OCC) has reported a study validating ‘high quality nerve repair’ from its CelGro treatment.
The pre-clinical study indicated CelGro facilitated the regeneration of severed peripheral nerves, returning them to normal nerve structure.
This reinforces earlier human trials that CelGro restored nerve sensation, reducing the need for sutures.
Orthocell managing director, Paul Anderson said: “We are thrilled with the animal study results.
“(They) reinforce the initial patient outcomes previously reported from our current human clinical trials.”
Clinical trials continue in the third quarter of 2019.
The new study appeared to extend Orthocell’s claim that CelGro would not only restore nerve sensation, as indicated in humans, but actually repair nerve damage, which was the animal trial outcome.
However the sharemarket was not convinced.
Orthocell’s shares spiked eight cents to 53 cents on the news, but eased back to their starting point of 45 cents late Friday.
Subscribe to our free @AuManufacturing newsletter here.